Abstract:Despite significant progress in targeted therapies, cancer recurrence remains a major cause of mortality worldwide. Identification of accurate biomarkers, through molecular profiling in healthy and cancer patient samples, will improve diagnosis and promote personalized medicine. While genetic and epigenetic alterations of DNA are currently exploited as cancer biomarkers, their robustness is limited by tumor heterogeneity. Recently, cancer-associated changes in RNA marks have emerged as a promising source of diagnostic and prognostic biomarkers. RNA epigenetics (also known as epitranscriptomics) is an emerging field in which at least 150 chemical modifications in all types of RNA (mRNA, tRNA, lncRNA, rRNA, and microRNA) have been detected. These modifications fine-tune gene expression in both physiological and pathological processes. A growing number of studies have established links between specific modified nucleoside levels in solid/liquid biopsies, and cancer onset and progression. In this review, we highlight the potential role of epitranscriptomic markers in refining cancer diagnosis and/or prognosis. RNA modification patterns may contain important information for establishing an initial diagnosis, monitoring disease evolution, and predicting response to treatment. Furthermore, recent developments in mass spectrometry allow reliable quantification of RNA marks in solid biopsies and biological fluids. We discuss the great potential of mass spectrometry for identifying epitranscriptomic biomarker signatures in cancer diagnosis. While there are various methods to quantify modified nucleosides, most are unable to detect and quantify more than one type of RNA modification at a time. Mass spectrometry analyses, especially GC-MS/MS and LC-MS/MS, overcome this limitation and simultaneously detect modified nucleosides by multiple reaction monitoring. Indeed, several groups are currently validating mass spectrometry methods that quantify several nucleosides at one time in liquid biopsies. The challenge now is to exploit these powerful analytical tools to establish epitranscriptomic signatures that should open new perspectives in personalized medicine. This review summarizes the growing clinical field of analysis of RNA modifications and discusses pre-analytical and analytical approaches, focusing in particular on the development of new mass spectrometry tools and their clinical applications.

Towards a druggable epitranscriptome: Compounds that target RNA modifications in cancer

The rise of epitranscriptomics: recent developments and future directions

Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance

The diverse landscape of RNA modifications in cancer development and progression

Advances in RNA therapeutics for modulation of 'undruggable' targets

Targeting RNA modifications with pharmacological agents: New frontiers in cancer therapy

The Regulation of Protein Translation and Its Implications for Cancer

Role of Main RNA Modifications in Cancer: N6-methyladenosine, 5-Methylcytosine, and Pseudouridine

Targeting RNA modifications in leukaemia: Epitranscriptomic drugs are the new kids on the block

Small Molecules that Regulate the N 6 -Methyladenosine RNA Modification as Potential Anti-Cancer Agents

RNA modification: mechanisms and therapeutic targets

The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities

Epitranscriptomics: A New Layer of microRNA Regulation in Cancer

Decoding the role of tRNA modifications in cancer progression

Pharmacoepitranscriptomic Landscape Revealing M6a Modification Could Be a Drug-Effect Biomarker for Cancer Treatment.

Mass Spectrometry-Based Pipeline for Identifying RNA Modifications Involved in a Functional Process: Application to Cancer Cell Adaptation

Quantifying RNA modifications by mass spectrometry: a novel source of biomarkers in oncology

The Regulation of RNA Modification Systems: The Next Frontier in Epitranscriptomics?

Epitranscriptomics in the development, functions, and disorders of cancer stem cells

Targeting RNA structures with small molecules

Detecting the epitranscriptome